牛牛AI助理已提取核心訊息
On December 29, 2023, The Vanguard Group filed an amended Schedule 13G/A with the SEC, indicating a change in their holdings of Altimmune Inc's common stock. The filing revealed that The Vanguard Group now beneficially owns 3,571,972 shares of Altimmune, which represents 6.65% of the company's class of common stock. This position is a mix of shared and sole voting and dispositive power, with the majority being sole dispositive power at 3,529,736 shares. The Vanguard Group, headquartered in Pennsylvania, is an investment adviser and reports that the securities were acquired in the ordinary course of business, not with the purpose of changing or influencing the control of Altimmune Inc. The updated ownership information was officially filed with the SEC on February 13, 2024.
On December 29, 2023, The Vanguard Group filed an amended Schedule 13G/A with the SEC, indicating a change in their holdings of Altimmune Inc's common stock. The filing revealed that The Vanguard Group now beneficially owns 3,571,972 shares of Altimmune, which represents 6.65% of the company's class of common stock. This position is a mix of shared and sole voting and dispositive power, with the majority being sole dispositive power at 3,529,736 shares. The Vanguard Group, headquartered in Pennsylvania, is an investment adviser and reports that the securities were acquired in the ordinary course of business, not with the purpose of changing or influencing the control of Altimmune Inc. The updated ownership information was officially filed with the SEC on February 13, 2024.
2023年12月29日，Vanguard集團向美國證券交易委員會提交了經修訂的附表13G/A，表明其持有的Altimmune Inc普通股發生了變化。文件顯示，Vanguard集團現在實益擁有Altimmune的3571,972股股份，佔該公司普通股類別的6.65％。該立場混合了共享和唯一投票權和處置權，其中多數是唯一的處置權，爲3,529,736股。總部位於賓夕法尼亞州的Vanguard Group是一家投資顧問，該公司報告稱，這些證券是在正常業務過程中收購的，其目的不是改變或影響Altimmune Inc.的控制權。更新的所有權信息已於2024年2月13日正式向美國證券交易委員會提交。
2023年12月29日，Vanguard集團向美國證券交易委員會提交了經修訂的附表13G/A，表明其持有的Altimmune Inc普通股發生了變化。文件顯示，Vanguard集團現在實益擁有Altimmune的3571,972股股份，佔該公司普通股類別的6.65％。該立場混合了共享和唯一投票權和處置權，其中多數是唯一的處置權，爲3,529,736股。總部位於賓夕法尼亞州的Vanguard Group是一家投資顧問，該公司報告稱，這些證券是在正常業務過程中收購的，其目的不是改變或影響Altimmune Inc.的控制權。更新的所有權信息已於2024年2月13日正式向美國證券交易委員會提交。
有用
沒用